#United States #New York #Pomerantz LLP #SEC Investigation #Unicycive Therapeutics

Pomerantz Law Firm Investigates Unicycive Therapeutics Amid SEC Concerns

In an emerging story that is capturing the attention of both financial analysts and investors, the Pomerantz Law Firm has initiated an investigation into Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This inquiry comes at a time when the company is facing serious allegations concerning its business practices, particularly in relation to securities fraud.

The investigation focuses on whether Unicycive and specific personnel within the firm have engaged in any wrongful acts that could have resulted in significant losses for shareholders. The impetus for this scrutiny was a press release from Unicycive dated June 30, 2025, where the company disclosed that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for a treatment aimed at hyperphosphatemia in chronic kidney disease patients on dialysis.

The FDA's letter outlined concerns that stemmed from a third-party manufacturing vendor connected to Unicycive, which was flagged for various deficiencies following a cGMP (current Good Manufacturing Practice) inspection. Such damaging news led to an immediate backlash in the stock market, triggering a $2.03 decrease in Unicycive's share price, equating to a staggering 29.85% drop and closing the stock at $4.77 on June 30, 2025.

Pomerantz LLP, recognized as one of the leading firms in handling corporate, securities, and antitrust class litigation, is urging anyone impacted by this recent downturn to come forward. Lead attorney Danielle Peyton is actively seeking communications from affected investors to discuss their possible involvement in a class-action lawsuit against Unicycive Therapeutics. Shareholders are encouraged to reach out directly through telephone at 646-581-9980 or via email at [email protected]

Founded over 85 years ago by Abraham L. Pomerantz, the firm has a storied legacy of advocating for victims of securities fraud and corporate malfeasance. The attorneys at Pomerantz have successfully navigated complex litigation landscapes, securing substantial awards for victims of corporate misconduct. Currently, they are applying their extensive experience to safeguard the rights of Unicycive investors.

As the investigation unfolds, it's critical for current and former shareholders to stay alert for updates related to this case. The developing situation raises significant questions about Unicycive’s corporate governance and whether the company will be held accountable for potential misrepresentations in the financial markets.

Moreover, this incident serves as a stark reminder of the inherent risks involved with investments in biopharmaceutical firms, particularly when they hinge on regulatory approvals that can dramatically impact stock value. Investors are advised to remain vigilant, monitor communications from the company, and consult with legal counsel as necessary.

For more information about the investigation and to understand your rights as a shareholder in Unicycive Therapeutics, visit www.pomlaw.com. Awaiting further developments, stakeholders are encouraged to assess their positions cautiously in light of recent events that could redefine the future of Unicycive Therapeutics and its shareholders.